Genetic Engineering News ... with metastatic melanoma, the company said. Further, the firm will also present Phase II safety and efficacy results on elotuzumab plus lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma, along with partner AbbVie. and more »
The Myeloma Beacon Most patients (89 percent) were initially treated with cyclophosphamide (Cytoxan) and dexamethasone (Decadron). However, none of the patients had previously received Velcade. Patients in the treatment group received 1.3 mg/m2 Velcade for six cycles.
Medscape One exception to the recommendation against routine prophylaxis is patients with multiple myeloma who are receiving thalidomide or lenalidomide along with chemotherapy and/or dexamethasone . For these patients, routine thromboprophylaxis with a LMWH ...
PR Newswire UK (press release) All patients received oral dexamethasone on day 1. The primary efficacy endpoint was complete response during the delayed phase. About the Pivotal Phase II Study. The Phase II study, which was designed to determine the proper dose of netupitant to ... and more »
MarketWatch (press release) Interviewed thought leaders are optimistic that the CRd regimen-- carfilzomib (Onyx Pharmaceuticals/Ono Pharmaceutical's Kyprolis) in combination with lenalidomide (Celgene's Revlimid) and dexamethasone --will show advantages over sales-leading ... and more »
Daily Mining Gazette Another treatment used is a single dose of intravenous Dexamethasone , which is a steroid. It is very important to note that opiates and barbiturates are not recommended in the treatment of migraine, as they give hyperalgesia, rebound and overuse ...
7thSpace Interactive (press release) Both dexamethasone and betamethasone, given to women at risk of preterm birth, substantially improve short-term neonatal health, increase the chance of the baby being discharged home alive, and reduce childhood neurosensory disability, remaining safe ...
Sacramento Bee Elotuzumab is being jointly developed by AbbVie and Bristol-Myers Squibb. About ABT-888 (Veliparib). Veliparib is an investigational oral poly ( adenosine diphosphate [ADP]–ribose) polymerases (PARPs) inhibitor being evaluated in multiple tumor types. and more »
